| Metric | Details |
|---|---|
| Entity / Legal Name | Grifols Shared Services North America, Inc. (BioMat USA) |
| Parent Company | Grifols, S.A. (NASDAQ: GRFS; BME: GRF) |
| S&P / Moody’s Rating (Grifols) | BB / Ba3 |
| Outlook | Negative (both agencies) |
| Investment Grade Status | Non-Investment Grade / High Yield |
| Sector | Plasma Collection / Biopharmaceuticals |
| US Center Count (BioMat USA) | 300+ |
| Cap Rate Range | 7.00–8.50% |
| Typical Lease Term | 10–15 years (NNN) |
| Guarantee Type | Grifols entity (confirm specific subsidiary) |
| Parent Annual Revenue | ~€7.1B (~$7.7B USD, FY2024) |
| Typical Building Size | 7,000–13,000 SF |
| Typical Price Range | $2,500,000–$6,500,000 |
Grifols Business Overview & NNN Investment Profile
Grifols, S.A. is a Barcelona, Spain-based global biopharmaceuticals company and the third-largest plasma-derived medicines manufacturer in the world, operating behind CSL Behring and Takeda in market share. In the United States, Grifols collects plasma through its BioMat USA subsidiary, which operates approximately 300+ plasma donation centers across the country. These BioMat USA centers supply raw source plasma to Grifols’ manufacturing operations, which produce albumin, immunoglobulins, clotting factors, and other plasma-derived therapies.
The Plasma Center NNN Comparison: Grifols vs. CSL vs. BioLife
The three major investment-grade and sub-investment-grade plasma collection NNN options present a clear credit and yield ladder:
| Plasma Tenant | Rating | Cap Rate Range | Price Range |
|---|---|---|---|
| CSL Plasma | A‑ / A3 | 5.25–6.25% | $3M–$7.5M |
| BioLife Plasma | BBB‑ / Baa3 | 5.75–6.75% | $3M–$7M |
| Grifols / BioMat USA | BB / Ba3 Neg. | 7.00–8.50% | $2.5M–$6.5M |
| Octapharma Plasma | Private / NR | 7.50–9.00% | $2.5M–$6M |
Grifols NNN Cap Rate & Pricing
Grifols / BioMat USA NNN properties trade at cap rates between 7.00% and 8.50% as of Q1 2026 — meaningfully wider than investment-grade CSL Plasma and BioLife, reflecting the BB/Ba3 Negative rating and the additional governance and leverage concerns at the Grifols parent level. Suburban locations with long remaining lease terms in high-traffic corridors price at the tighter end. The negative rating outlook warrants a premium above the standard BB/Ba3 range. Acquisition prices of $2,500,000 to $6,500,000 provide accessible entry below the investment-grade plasma alternatives.
Is Grifols investment grade?
No. Grifols carries BB from S&P and Ba3 from Moody’s — both with negative outlooks, indicating additional downgrade risk. NNN investors should factor in the potential for further credit deterioration and compare carefully against investment-grade plasma alternatives like CSL Plasma (A‑/A3) and BioLife (BBB‑/Baa3).
What brand name does Grifols use for its US plasma centers?
Grifols operates its US plasma collection centers under the BioMat USA brand. All BioMat USA center NNN leases are guaranteed by Grifols’ US subsidiary. Investors should confirm the specific guarantor entity on the lease and verify it carries the parent Grifols credit support.
The Only Grifols / BioMat USA NNN Advisor Whose Fee Comes From the Deal, Not From You
In NNN buyer representation, the listing broker pays the cooperating commission.
Find It — Grifols / BioMat USA NNN centers sourced with guarantor entity confirmation and lease term analysis. Given the BB/Ba3 Negative rating, we verify the guarantee chain before you commit.
Compare It — Not certain Grifols is the right credit tier? We show you BioLife and CSL Plasma alternatives side-by-side to find the right yield–risk balance for your criteria.
Talk to a Plasma NNN Specialist →
In a 1031 exchange? Tell us your timeline — we move faster.
Related NNN Tenants
- Ascension
- Aspen Dental
- Athletico
- BioLife Plasma
- Concentra / Humana
- Corewell Health
- CSL Plasma
- DaVita Dialysis
- EyeCare Partners
- Fresenius
- Henry Ford Health
- HCA Healthcare
- Heartland Dental
- Mary Washington Healthcare
- McLaren Health Care
- Oak Street Health
- Piedmont Healthcare
- Sparrow Health
- Trinity Health
- U of M Health
- University of Pittsburgh Medical Center (UPMC)
- Acadia Healthcare
- AFC Urgent Care
- ATI Physical Therapy
- CityMD / Summit Health
- Encompass Health
- Fast Pace Urgent Care
- MedExpress Urgent Care
- MyEyeDr
- NextCare Urgent Care
- Octapharma Plasma
- Pacific Dental Services
- Select Physical Therapy
- Smile Brands
- VCA Animal Hospitals
- WellNow Urgent Care
- Banfield Pet Hospital
- Labcorp
- National Vision
- Quest Diagnostics
Own a Grifols Plasma Property? Capital Markets Strategies Beyond Selling
Maturing debt and considering refinancing? Our capital markets team maintains 150+ lender relationships underwriting NNN properties across investment-grade and non-investment-grade credit tiers. We structure rate-and-term refinancing, cash-out refis, and bridge-to-perm takeouts.
Evaluating a 1031 exchange or disposition? We represent both sides of Grifols Plasma NNN transactions — whether you are looking to exit at peak value, exchange into a higher-quality credit tenant, or reposition within the same sector.
Need a current valuation? We maintain live comps on Grifols Plasma NNN transactions and can produce a Broker Opinion of Value within 48 hours reflecting today’s cap rate market.
Own multiple Grifols Plasma properties? Considering an off-market sale?
Investment Grade represents owners on confidential disposition of Grifols Plasma portfolios and individual properties through off-market direct-to-principal distribution to specialty REITs, private equity funds, and family offices. Grifols Plasma buyer demand runs deep, and portfolio sales consistently produce stronger pricing than sequential individual sales because the institutional buyer pool is structured around portfolio acquisition.
For multi-property owners considering a portfolio disposition, see Selling Investment Grade NNN Off-Market: Tenant-by-Tenant Buyer Demand. For the full off-market framework covering individual property dispositions, sale-leasebacks, and 1031 coordination, see Off-Market CRE Sales: The Complete 2026 Guide.
The pre-listing conversation is at no cost and fully confidential. Email team@investmentgrade.com or see contact Investment Grade.
